Aldo Badano, Ph.D.

In silico trials (ISTs) for medical drugs and devices have gained increased popularity as cost-effective alternatives to their clinical counterparts. ISTs promise dramatic reductions in the resources needed for assessing novel technologies and for generating evidence in support of regulatory evaluation for safety and effectiveness. Some have suggested significant cost reductions comparing an all in silico approach versus an equivalent clinical trial with humans. Others have argued for, and reported on, incremental implementation of the in silico methodologies that complement or refine the design of clinical trials based on predictions from the in silico trial outcomes.

This webinar has been launched in collaboration with a special issue in Progress in Biomedical Engineering, a new high-impact Reviews journal from IOP Publishing. The special issue is still welcoming article proposals from the community, and participants are encouraged to discuss contributions with the guest editors… Continue reading.

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Aldo Badano, Ph.D., Deputy Director, DIDSR/OSEL/CDRH, Food and Drug Administration, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Badano was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contributions to the development of novel approaches for the assessment and regulatory approval of medical imaging devices.“